Drug intelligence / Profile preview

LH-1802

Development stage: Unknown
Lead developer: Jiangsu Lianhuan Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

LH-1802 is an orally bioavailable small molecule inhibitor of the Menin-KMT2A (formerly MLL1) protein-protein interaction. Developed by Jiangsu Lianhuan Pharmaceutical, it is currently in Phase 1 clinical development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The therapeutic rationale focuses on patients with KMT2A rearrangements (KMT2Ar) or NPM1 mutations, where the Menin-KMT2A complex drives the expression of HOXA and MEIS1 genes, maintaining a leukemic state. By competitively binding to Menin, LH-1802 disrupts this complex, leading to the downregulation of leukemogenic genes and inducing the differentiation of myeloid blasts.

Targets

MEN1 (Menin)

Beyond the preview

Go deeper on LH-1802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LH-1802.

Explore the full profile